Overview

Subcutaneous Immunoglobulin for CIDP

Status:
Completed

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

The investigators are using self administered subcutaneous IG in patients with CIDP who require IVIG. Safety, efficacy, and patient satisfaction will be examined.

Phase:

N/A

Details

Lead Sponsor:

University of South Florida

Collaborator:

CSL Behring

Treatments:

Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin